CLINICAL TRIALS PROFILE FOR VAMOROLONE
✉ Email this page to a colleague
All Clinical Trials for VAMOROLONE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT02760264 ↗ | A Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD) | Completed | Cooperative International Neuromuscular Research Group | Phase 2 | 2016-06-01 | The purpose of this study is to determine whether a new medication called vamorolone is safe and well-tolerated by boys with Duchenne muscular dystrophy (DMD) ages ≥ 4 and < 7 years old. |
| NCT02760264 ↗ | A Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD) | Completed | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | Phase 2 | 2016-06-01 | The purpose of this study is to determine whether a new medication called vamorolone is safe and well-tolerated by boys with Duchenne muscular dystrophy (DMD) ages ≥ 4 and < 7 years old. |
| NCT02760264 ↗ | A Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD) | Completed | National Institute of Neurological Disorders and Stroke (NINDS) | Phase 2 | 2016-06-01 | The purpose of this study is to determine whether a new medication called vamorolone is safe and well-tolerated by boys with Duchenne muscular dystrophy (DMD) ages ≥ 4 and < 7 years old. |
| NCT02760264 ↗ | A Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD) | Completed | University of Pittsburgh | Phase 2 | 2016-06-01 | The purpose of this study is to determine whether a new medication called vamorolone is safe and well-tolerated by boys with Duchenne muscular dystrophy (DMD) ages ≥ 4 and < 7 years old. |
| NCT02760264 ↗ | A Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD) | Completed | ReveraGen BioPharma, Inc. | Phase 2 | 2016-06-01 | The purpose of this study is to determine whether a new medication called vamorolone is safe and well-tolerated by boys with Duchenne muscular dystrophy (DMD) ages ≥ 4 and < 7 years old. |
| NCT02760277 ↗ | An Extension Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD) | Completed | Cooperative International Neuromuscular Research Group | Phase 2 | 2016-07-28 | The main purposes of this study are to see if it is safe to use a new medication called vamorolone for more than two weeks in children with Duchenne muscular dystrophy (DMD), to see if vamorolone works for the treatment for DMD, and to see how any potential side effects compare to those seen in boys using steroids. |
| NCT02760277 ↗ | An Extension Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD) | Completed | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | Phase 2 | 2016-07-28 | The main purposes of this study are to see if it is safe to use a new medication called vamorolone for more than two weeks in children with Duchenne muscular dystrophy (DMD), to see if vamorolone works for the treatment for DMD, and to see how any potential side effects compare to those seen in boys using steroids. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for VAMOROLONE
Condition Name
Clinical Trial Locations for VAMOROLONE
Trials by Country
Clinical Trial Progress for VAMOROLONE
Clinical Trial Phase
Clinical Trial Sponsors for VAMOROLONE
Sponsor Name
